Core A will serve all projects and cores in the Novel neuroAIDS Therapies: Integrated Preclinical/Clinical IPCP and will be responsible for oversight ofthe scientific, administrative, regulatory and operational aspects of the program's activities. The overall goal of the Administrative Core is to enable the IPCP to fulfill its scientific mission, as defined in the introduction and overview at the beginning of this proposal, as a specified in the Specific Aims of the three projects. The Principal Investigator, Dr. Steven D. Douglas, will direct this core and will provide leadership, direction, and organization to the overall program project effort and assist each of the Project Leaders and Core Leaders in the successful execution of their planned experiments or support services. The objectives ofthe Administrative Core are to: (1) Coordinate and supervise this IPCP; (2) Oversee the development plan ofthe IPCP by coordinating regular review of study results and integration of this information into the decision-making process that is integral to the drug development mission of the research program;(3) Promote a high degree of collaboration and synergistic interaction among the investigators and core leaders;(4) Facilitate participation of this IPCP within NIH IPCP Program activities;(5) Insure efficient and appropriate use of core services by the individual projects;(6) Provide investigators and core directors with timely and accurate information regarding core and project expenditures and resources; (7) Insure that the program's development plan is conducted in compliance with all applicable regulatory guidelines and NIH policies and procedures;(8) Organize and implement regular internal and external oversight of the IPCP's activities;and, (9) Support the program in fulfilling its obligations related to information dissemination, scientific publication and data sharing. This will include management of intellectual property issues in collaboration with the CHOP Department of Technology Transfer. The Administrative Core will be utilized equally by all participating projects and scientific cores.
An Administrative Core is essential to the functioning of the IPCP. Its role is to foster excellence in communication, decision-making and resource allocation and to assure that the program achieves its scientific mission. Innovation and synergy in a collaborative research effort depend on regular information sharing, review of progress, and the ability to assimilate and re-direct research as necessary to meet milestones and timelines. The Administrative Core provides the engine that drives these functions.
|Barrett, Jeffrey S; Spitsin, Sergei; Moorthy, Ganesh et al. (2016) Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med 14:148|
|Douglas, Steven D (2016) Substance P and sickle cell disease-a marker for pain and novel therapeutic approaches. Br J Haematol 175:187-188|
|McGuire, Jennifer L; Gill, Alexander J; Douglas, Steven D et al. (2015) Central and peripheral markers of neurodegeneration and monocyte activation in HIV-associated neurocognitive disorders. J Neurovirol 21:439-48|
|Tebas, Pablo; Spitsin, Sergei; Barrett, Jeffrey S et al. (2015) Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults. AIDS 29:931-9|
|McGuire, Jennifer L; Kempen, John H; Localio, Russell et al. (2015) Immune markers predictive of neuropsychiatric symptoms in HIV-infected youth. Clin Vaccine Immunol 22:27-36|
|Tuluc, Florin; Meshki, John; Spitsin, Sergei et al. (2014) HIV infection of macrophages is enhanced in the presence of increased expression of CD163 induced by substance P. J Leukoc Biol 96:143-50|
|McGuire, Jennifer L; Barrett, Jeffrey S; Vezina, Heather E et al. (2014) Adjuvant therapies for HIV-associated neurocognitive disorders. Ann Clin Transl Neurol 1:938-52|
|Barrett, Jeffrey S; Bajaj, Gaurav; McGuire, Jennifer et al. (2014) Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant. Curr HIV Res 12:121-31|
|Barrett, Jeffrey S; McGuire, Jennifer; Vezina, Heather et al. (2013) PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions? J Clin Psychopharmacol 33:725-8|
|Schwartz, Lynnae; Spitsin, Sergei V; Meshki, John et al. (2013) Substance P enhances HIV-1 infection in human fetal brain cell cultures expressing full-length neurokinin-1 receptor. J Neurovirol 19:219-27|
Showing the most recent 10 out of 16 publications